Description: LCS3 is a reversible and non-competitive synergistic inhibitor of glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) with IC50s of 3.3 µM and 3.8 µM, respectively. LCS3 has antitumour activity, induces apoptosis and can be used in the study of lung adenocarcinoma (LUAD). Target:...

LCS3 is an inhibitor of glutathione reductase (GR) and thioredoxin reductase (TrxR, IC50s = 3.3 and 3.8 µM, respectively). It decreases the glutathione (GSH) to oxidized GSH (GSSG) ratio in NCI H1650 and H23 lung adenocarcinoma cells in a concentration-dependent manner. LCS3 (3 µM) induces apoptosis in NCI H1650 and...